Patents by Inventor Eunhwa Ko

Eunhwa Ko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10870647
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: December 22, 2020
    Assignee: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-Ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Publication number: 20200325130
    Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 15, 2020
    Inventors: Craig CREWS, Momar TOURE, Eunhwa KO, Saul JAIME-FIGUEROA
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Publication number: 20200207756
    Abstract: The present invention relates to a pyrrolopyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 2, 2020
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Publication number: 20190315738
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 17, 2019
    Applicant: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Publication number: 20190016703
    Abstract: The present invention provides bifunctional compounds which act as protein degradation inducing moieties for a HER family protein, such as Her3. The present invention also provides methods for the targeted degradation of a HER family protein through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to the HER family protein which can be utilized in the treatment of disorders modulated by a HER family protein.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 17, 2019
    Inventors: Nathanael S. GRAY, James BRADNER, Pasi JANNE, Jaebong JANG, Hwan Geun CHOI, Eunhwa KO, Joong-Heui CHO
  • Patent number: 10071164
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 11, 2018
    Assignees: Yale University, Arvinas, Inc.
    Inventors: Andrew Crew, Craig Crews, Hanqing Dong, Eunhwa Ko, Jing Wang
  • Publication number: 20180186785
    Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: Craig CREWS, Momar TOURE, Eunhwa KO, Saul JAIME-FIGUEROA
  • Patent number: 9938264
    Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: April 10, 2018
    Assignee: Yale University
    Inventors: Craig Crews, Momar Toure, Eunhwa Ko, Saul Jaime-Figueroa
  • Publication number: 20170121321
    Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventors: Craig CREWS, Momar TOURE, Eunhwa KO, Saul Jaime-Figueroa
  • Publication number: 20160045607
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: August 10, 2015
    Publication date: February 18, 2016
    Inventors: Andrew Crew, Craig Crews, Hanqing Dong, Eunhwa Ko, Jing Wang